Jam
-
Western Alliance Bank Finances Affordable Housing Project in North Las Vegas
Western Alliance Bank is financing the Senator Joseph M. Neal Jr. Apartments, a 192-unit affordable housing project in North Las Vegas, scheduled to open in Fall 2027. The bank’s investment includes the purchase of tax-exempt bonds and tax credit equity. The community, named after Nevada’s first Black state senator, will feature one- and two-bedroom units with amenities and prioritize senior residents. The project addresses Las Vegas’s affordable housing shortage via a partnership between public and private sectors, offering units for residents earning below the area median income, with many benefiting from HUD Section 8 assistance.
-
K12 Earns Two Silver Medals at the 2025 International Serious Play Awards
K12 (LRN) received two Silver Medals at the 2025 International Serious Play Awards for its K12 ELA Village and K12 Coordinate Islands world for Minecraft Education. These games target grades 2-5, utilizing Science of Reading principles and standards-aligned gameplay to enhance English language arts and mathematics skills. K12 ELA Village focuses on grammar and vocabulary, while Coordinate Islands teaches graphing concepts. K12 has served over 3 million students, providing interactive and engaging learning experiences.
-
Cleghorn Reduces Stock Option Grants to Adelaide Capital Markets Inc.
Cleghorn Minerals (OTC:CLGMF) reduced incentive stock options granted to Adelaide Capital Markets from 100,000 to 64,800, exercisable at $0.05 per share and expiring October 10, 2030. This adjustment complies with TSX Venture Exchange regulations. The revised option number reflects a possible recalibration of the advisory relationship, adoption of a conservative approach to potential advisory fees due to the performance of Cleghorn Mineral’s stock, or failure to meet initially agreed upon milestones. The long-term expiration indicates optimism regarding Cleghorn’s development prospects.
-
FB Financial Corporation Announces Regular Quarterly Dividend
FB Financial Corporation (FBK) declared a $0.19 per share quarterly cash dividend, payable November 25, 2025, to shareholders of record as of November 11, 2025. CEO Christopher T. Holmes cites the dividend as a reflection of the company’s strong performance and commitment to shareholder returns. The announcement arrives amid increased scrutiny of regional banks, with analysts watching key performance indicators to assess the long-term sustainability of FBK’s dividend policy in a challenging financial environment. FB Financial, with $16.2 billion in assets and 91 branches, operates in the Southeast.
-
Prince Silver Aims for Maiden Resource by Mid-2026, Targeting 43M+ Tonne CRD Silver Deposit (CEO.CA’s Inside the Boardroom)
CEO.CA featured Prince Silver Corp (PRNC) in its “Inside the Boardroom” series, highlighting the company’s aim to define an initial resource estimate by mid-2026. Prince Silver is targeting a potential 43+ million tonne Carbonate Replacement Deposit (CRD) silver deposit. The interview provides insights into Prince Silver’s strategy amid increasing investor interest in silver due to its precious metal and industrial applications. CEO.CA, a platform for investors in emerging markets, facilitates information sharing and connects investors with companies.
-
Autohome Inc. Announces Third Quarter 2025 Financial Results Release Date
Autohome Inc. (ATHM; 2518.HK) will release its Q3 2025 financial results on November 6, 2025, before U.S. markets open. A conference call will be held at 7:00 AM ET. Analysts are focusing on the company’s performance in a changing Chinese automotive market, including the effectiveness of its AI content strategy and the success of Autohome Mall. A live and archived webcast will be available at https://ir.autohome.com.cn. Autohome is adapting to increased EV adoption and competition, striving to diversify its revenue beyond advertising.
-
Barrick Gold Continues Successful Exploration at Tembo-Area Licenses in Lake Victoria Region
Lake Victoria Gold reported exploration updates from Bulyanhulu Gold Mine (Barrick/Twiga owned) on six licenses acquired from LVG. Q2 2025 saw 12 RC holes drilled (1,380m) targeting the granite-greenstone contact, revealing mafic metavolcanics and alteration. LVG may receive up to US$45M in contingent payments based on future discoveries. Barrick will prioritize identified targets in Q3 2025. The drilling confirms geological continuity and validates long-standing interpretations of the belt’s potential.
-
Norsk Hydro: Steady Performance Despite Market Volatility
Norsk Hydro’s Q3 2025 adjusted EBITDA decreased to NOK 5,996m due to lower alumina prices and a stronger NOK, while free cash flow remained strong at NOK 2.2bn, and net debt reduced to NOK 13.6bn. The company launched a cost reduction program targeting NOK 1bn annual savings from 2026 and secured a power agreement for Alouette through 2045. A Rotterdam court dismissed all 2021 claims against Hydro. They also divested Corvus Energy for USD 30m.
-
Linear Minerals Corp. Announces AGM Results and Shareholder Approval of Plan of Arrangement
Linear Minerals Corp. shareholders approved a strategic restructuring at their annual meeting, including the spin-out of the Pontax West Lithium Property into a new subsidiary, Westlinear Minerals Corp. (Spinco). Shareholders will receive 1 Spinco share for every 10 Linear shares. Gurminder Sangha and four other directors were re-elected. The arrangement is subject to court and exchange approvals, and the Share Distribution Record Date will be announced later. This move aims to enhance focus and growth potential for both entities.
-
US FDA Approves Blenrep for Relapsed/Refractory Multiple Myeloma
GSK’s *Blenrep* (belantamab mafodotin-blmf) has received FDA approval for relapsed or refractory multiple myeloma patients after at least two prior therapies. Backed by the DREAMM-7 trial, *Blenrep* combined with bortezomib and dexamethasone showed a 51% reduction in death risk and tripled progression-free survival compared to a daratumumab-based triplet. *Blenrep* is the only anti-BCMA agent accessible in community settings, with a streamlined REMS program. GSK is actively developing *Blenrep* for earlier lines of treatment, with ongoing trials and data expected in the coming years.